MedTrace Logo

PRediction Of Five Usual Tumors Using Blood Test for Risk Assessment and Early Detection

NCT05874648 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 3830

Last updated 2023-05-25

No results posted yet for this study

Summary

Liquid biopsy technology based on cell-free nucleic acids and protein characteristics has unique advantages and significant application prospects in cancer early detection. The purpose of this study is to collect peripheral blood samples from participants with new diagnosis of cancer and from participants who do not have a diagnosis of cancer in order to develop machine learning models for discovering cancer from non-cancer.

Conditions

Interventions

DEVICE

Multi-cancer early detection test

Blood collection and multi-cancer early detection test

Sponsors & Collaborators

  • Shanghai Weihe Medical Laboratory Co., Ltd.

    collaborator INDUSTRY

  • Sixth Affiliated Hospital, Sun Yat-sen University

    lead OTHER

Eligibility

Min Age
40 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-07-07
Primary Completion
2024-04-30
Completion
2024-10-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05874648 on ClinicalTrials.gov